Ledipasvir (formerly GS-5885), Treatment of chronic Hepatitis C infection

Standard

New Drug Approvals

File:Ledipasvir.svg

Ledipasvir (formerly GS-5885), Treatment of chronic Hepatitis C infection

Ledipasvir nonproprietary drug name

http://www.ama-assn.org/resources/doc/usan/ledipasvir.pdf

November 28, 2012. N12/139. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL. USAN ZZ-132. LEDIPASVIR.

MOLECULAR FORMULA C49H54F2N8O6
MOLECULAR WEIGHT 889
Gilead Sciences
CODE DESIGNATION GS-5885
CAS REGISTRY NUMBER 1256388-51-8

Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences.[1] It is currently in Phase III clinical trials.[2] It is being studied in combination with other direct-acting antiviral agents that interfere with HCV replication.

Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.

Ledipasvir is being tested in interferon-free regimens with other direct-acting antiviral agents for hepatitis C.

Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the HCV protease inhibitor sofosbuvir, ledipasvir…

View original post 121 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s